GlassScriptPhysician profile
Jaffar Hilli
NPI 1952657462
$5,112.87
in general payments reported to CMS, 2019-2025
44 companies · $28.12 in 2025
The $28.12 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2021: $104 · 2022: $1,059 · 2023: $2,692 · 2024: $535 · 2025: $28.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.11 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.16 | 2022-2023 | Lynparza, Enhertu |
| Amgen INC. | $336.46 | 2019-2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $294.18 | 2022-2023 | Myrisk |
| Celgene Corporation | $286.96 | 2022-2024 | Reblozyl, Opdualag |
| Seagen INC. | $281.02 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $268.10 | 2019-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $231.38 | 2019-2023 | Carvykti, Darzalex, Tecvayli |
| Genentech USA, INC. | $224.99 | 2019-2024 | Perjeta, Phesgo |
| Array Biopharma INC | $191.10 | 2019-2024 | Braftovi, Lorbrena, Mektovi |
| Telix Pharmaceuticals | $183.26 | 2023-2024 | Illuccix |
| Pfizer INC. | $178.15 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.94 | 2019 | |
| Glaxosmithkline, LLC. | $164.49 | 2022-2024 | Zejula, Jemperli, Nucala |
| Novartis Pharmaceuticals Corporation | $140.60 | 2019-2024 | |
| Exelixis INC. | $137.31 | 2023 | Cabometyx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.14 | 2022-2024 | Opdivo |
| Daiichi Sankyo INC. | $112.23 | 2022-2024 | Injectafer |
| Karyopharm Therapeutics INC. | $107.90 | 2022-2023 | Xpovio |
| Medtronic, INC. | $104.05 | 2021 | |
| Taiho Oncology, INC. | $96.86 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $86.45 | 2022-2023 | Xarelto |
| Ucb, INC. | $85.76 | 2023-2024 | Rystiggo |
| Regeneron Healthcare Solutions, INC. | $85.71 | 2022-2024 | Libtayo |
| Gilead Sciences, INC. | $79.12 | 2022-2024 | Trodelvy |
| Adc Therapeutics America, INC. | $77.73 | 2022-2024 | |
| Shield Therapeutics INC | $63.40 | 2023 | Accrufer |
| Eisai INC. | $62.10 | 2023 | |
| Tersera Therapeutics LLC | $60.45 | 2022-2023 | Zoladex |
| Lilly USA, LLC | $46.93 | 2023-2024 | Jaypirca, Verzenio, Cyramza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.49 | 2023 | Gilotrif |
| Alnylam Pharmaceuticals INC. | $45.57 | 2023 | Givlaari |
| Mirati Therapeutics, INC. | $40.81 | 2023 | Krazati |
| Acrotech Biopharma INC. | $34.33 | 2022-2023 | Beleodaq |
| Abbvie INC. | $33.38 | 2022 | |
| Astellas Pharma US INC | $29.41 | 2023 | Xospata, Xtandi |
| Tempus Ai, INC | $28.12 | 2025 | Xt Cdx |
| Incyte Corporation | $24.08 | 2023 | Jakafi |
| Servier Pharmaceuticals LLC | $22.18 | 2023 | |
| Puma Biotechnology, INC. | $20.79 | 2023 | |
| Immunogen, INC. | $20.57 | 2024 | Elahere |
| Cti Biopharma Corp. | $17.74 | 2023 | Vonjo |
| Horizon Therapeutics Plc | $16.38 | 2022 | |
| Janssen Scientific Affairs, LLC | $16.31 | 2019 | |
| Morphosys, US INC. | $15.78 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaffar Hilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.